Please assess the completion status of the following clinical trial:

Trial Title: Frontline Clinician Psilocybin Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must be physicians or nurses with at least 1 month of frontline clinical experience during the COVID pandemic who rate at least 2 of 4 items from the COVID Exposure index as 'more than half the days' during their peak 2 week period of exposure: i. Caring for someone critically ill with COVID-19, or who became critically ill while you were involved; ii. Working longer hours than usual in order to provide assistance or care to individuals with COVID-19; iii. Witnessing or responding to a death related to COVID-19, or losing a patient you had been caring for to COVID-19; iv. Caring for patients who have died without family physically present due to COVID-19 precautions~2. Have a Montgomery-Asberg Depression Rating Scale (MADRS) clinician-administered depression score \>21, indicating moderately severe symptoms.~3. Have had persistent symptoms despite at least one medication and/or therapy trial of standard care treatment for depression.~4. English speaking - able to understand the process of consent and the risk and benefits associated with the study, and able to give written informed consent.~5. Must be willing to sign a medical release for the investigators to communicate directly with their therapist and doctors to confirm a medication and/or medical history. This is decided on a case-by-case basis upon the discretion of the PI.~6. Must be driven home after the medication dosing session by a driver (which could be a friend, family, rideshare or taxi).~7. Must provide at least one adult to have continuous contact with the participant, provide participant transportation, monitor changes in the participant's behavior, and notify research staff of behavior changes.~8. Has been off selective serotonin inhibitors (SSRIs) for at least five half-lives of the drug plus 2 weeks.~9. Must avoid taking any psychiatric medications or starting a new psychiatric medication during the study. Should participant's doctor recommend starting a new psychiatric medication, participant will be required to notify the study team and the subject would withdraw from the study~10. Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the Clinical Investigators in the event of a participant becoming suicidal.~11. If able to bear children, must have a negative pregnancy test at study entry.~12. Are willing to commit to preparation sessions, medication dosing sessions, integration sessions, to complete evaluation instruments and commit to be contacted for all necessary telephone contacts.~Exclusion Criteria:~1. Personal or immediate family history of schizophrenia, bipolar affective disorder, delusion disorder, paranoid disorder, or schizoaffective disorder.~2. Suicidal ideation with a Columbia Suicide Severity Rating Scale (C-SSRS) \> 3~3. Current substance abuse disorder (except in the case of mild alcohol use )~4. Neuroleptic and SSRI medications that cannot be tapered and discontinued in conjunction with the participant's prescribing physician.~5. Unstable neurological or medical condition; history of seizure, chronic/severe headaches.~6. Positive urine pregnancy test at the time of screening~7. Any unstable medical condition that my render study procedures unsafe.~8. Any use of psychedelic drugs within the prior 12 months.~9. Use of tramadol, due to the potential for serotonin syndrome with concomitant use of psilocybin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Psilocybin arm (Type: EXPERIMENTAL): psychedelic assisted psychotherapy + 25mg psilocybin
- Placebo (Type: ACTIVE_COMPARATOR): Psychedelic assisted psychotherapy + 250mg niacin

Based on this trial design, predict the completion outcome and termination type (if applicable).